Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2024 07:48 ET | Source: Praxis Bioresearch, Inc.

Praxis Bioresearch Obtains FDA Clearance On the IND Application for Its Lead Candidate PRX-P4-003 In Alzheimer’s Disease Apathy

LOS ANGELES, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for...
November 09, 2021 07:00 ET | Source: Praxis Bioresearch, LLC

Praxis Bioresearch Presents Phase 0 Clinical Data for PRX-P4-003 at 14th Annual CTAD conference

LOS ANGELES, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports Clinical Phase 0 study data (PBR001) to demonstrate the desired pharmacokinetic profile for its lead product candidate,...
August 05, 2021 04:00 ET | Source: Praxis Bioresearch, LLC

Praxis Bioresearch Awarded $2.9 Million Fast-Track SBIR Grant for Development of Novel Therapy for Apathy in Alzheimer’s Disease

LOS ANGELES, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Praxis is proud to announce to be the recipient of a Fast-Track SBIR award to develop treatment for apathy in Alzheimer’s Disease. The award, in its...
June 23, 2021 06:07 ET | Source: Praxis Bioresearch, LLC

Praxis Bioresearch Announces Positive Results from Clinical Microdose Study in Humans Showing Oral Activation of Its Novel Prodrug Stimulant PRX-P4-003

All subjects who were dosed with Prodrug PRX-P4-003 had systemic exposure of the active moiety (-)-fencamfamine suggesting robust intestinal conversionAs anticipated, fed subjects showed earlier...